Aquestive Therapeutics

Transform lives through pharmaceutical innovation by becoming the global leader in complex therapeutics

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Sub organizations:

SWOT Analysis

Updated: September 18, 2025 • 2025-Q3 Analysis

This SWOT Analysis reveals Aquestive's critical inflection point. Their proprietary PharmFilm technology represents a significant competitive moat, yet over-reliance on Suboxone Film creates dangerous vulnerability. The growing CNS therapeutics market offers substantial opportunities, but execution requires immediate action. Strategic priorities must focus on pipeline diversification, operational efficiency, and strategic partnerships. The company's innovative platform positions them well for future growth, but financial constraints demand disciplined capital allocation. Success hinges on transforming their technology leadership into sustainable commercial advantage while building resilience against competitive pressures. Bold strategic moves are essential to capture market opportunities before resource constraints limit options.

Indivior Titan Pharmaceuticals BioDelivery Sciences Catalent Patheon

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

Transform lives through pharmaceutical innovation by becoming the global leader in complex therapeutics

Toggle Theme

Strengths

TECHNOLOGY: Proprietary PharmFilm platform with 100+ patents portfolio
MANUFACTURING: FDA-approved integrated facility in Warren, New Jersey
EXPERTISE: Strong CNS therapeutic development and commercialization
PARTNERSHIPS: Established relationships with major pharmacy chains
PIPELINE: Diversified product portfolio across multiple indications

Weaknesses

REVENUE: Heavy dependence on single Suboxone Film product line
PROFITABILITY: Consistent net losses impacting financial stability
SCALE: Limited commercial infrastructure for market expansion
COMPETITION: Facing generic competition pressure on key products
CAPITAL: Constrained resources limiting R&D investment capacity

Opportunities

MARKET: Growing opioid addiction treatment market worth $4.2 billion
EXPANSION: International market opportunities for PharmFilm tech
PARTNERSHIPS: Potential licensing deals with major pharmaceutical
PIPELINE: Multiple Phase II/III trials showing positive results
REGULATION: FDA fast-track designations accelerating approvals

Threats

GENERIC: Generic competition eroding Suboxone Film market share
REGULATORY: Stricter FDA requirements increasing development costs
FUNDING: Limited access to capital markets for growth initiatives
COMPETITION: Large pharma companies entering CNS therapeutic space
REIMBURSEMENT: Insurance coverage challenges for specialty drugs

Key Priorities

DIVERSIFY: Accelerate pipeline development to reduce Suboxone dependence
PARTNERSHIPS: Secure strategic alliances for commercial expansion
EFFICIENCY: Optimize operations to achieve profitability targets
INNOVATION: Leverage PharmFilm platform for new therapeutic areas

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Strategic OKR Plan

Updated: September 18, 2025 • 2025-Q3 Analysis

This SWOT Analysis-driven OKR plan addresses Aquestive's critical strategic imperatives with precision and urgency. Revenue diversification tackles their dangerous Suboxone dependence while profitability focus ensures sustainable operations. Strategic partnerships amplify their limited resources through collaborative leverage. AI integration positions them for future competitive advantage. These objectives create a balanced approach between immediate financial stability and long-term innovation leadership. Execution requires disciplined resource allocation and bold partnership strategies to maximize impact across all fronts.

Indivior Titan Pharmaceuticals BioDelivery Sciences Catalent Patheon

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

Transform lives through pharmaceutical innovation by becoming the global leader in complex therapeutics

DIVERSIFY REVENUE

Reduce Suboxone dependence through pipeline acceleration

TRIALS: Complete Phase III enrollment for 2 pipeline candidates by Q3 2025
PARTNERSHIPS: Secure 1 major licensing deal worth minimum $10M upfront payment
COMMERCIALIZATION: Launch 1 new product generating $5M quarterly revenue
PORTFOLIO: Advance 3 clinical programs to next development phase

ACHIEVE PROFITABILITY

Optimize operations to reach sustainable break-even

COSTS: Reduce operating expenses by 15% through efficiency initiatives
MANUFACTURING: Improve production yield rates to 95% consistency
MARGINS: Increase gross margins to 70% through pricing optimization
EFFICIENCY: Implement AI-driven manufacturing processes reducing waste 20%

EXPAND PARTNERSHIPS

Build strategic alliances for commercial growth

ALLIANCES: Sign 2 strategic partnerships with major pharmaceutical companies
LICENSING: Generate $15M in licensing revenue from PharmFilm technology
DISTRIBUTION: Expand pharmacy network coverage to 85% of US market
INTERNATIONAL: Establish European market entry through partnership deal

LEVERAGE AI INNOVATION

Integrate AI capabilities for competitive advantage

PLATFORM: Deploy AI-powered formulation optimization system by Q2 2025
TRIALS: Implement machine learning for clinical trial patient selection
PARTNERSHIP: Establish AI technology collaboration with leading tech company
EFFICIENCY: Achieve 25% reduction in drug development timelines through AI

METRICS

Total Revenue: $75M
Net Income: Break-even
Pipeline Advancement: 5 programs

VALUES

Innovation Excellence
Patient-Centered Focus
Scientific Integrity
Collaborative Partnerships
Operational Excellence

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Aquestive Therapeutics Retrospective

AI-Powered Insights

Claude

Gemini

GPT

SEC 10-K and 10-Q filings for financial performance data
Company earnings calls and investor presentations
FDA drug approval databases and clinical trial records
Industry reports from pharmaceutical market research firms
Patent databases for intellectual property analysis
Competitive intelligence from pharmaceutical trade publications

Indivior Titan Pharmaceuticals BioDelivery Sciences Catalent Patheon

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

Transform lives through pharmaceutical innovation by becoming the global leader in complex therapeutics

Toggle Theme

What Went Well

REVENUE: Suboxone Film maintained stable revenue performance
PIPELINE: Advanced multiple clinical programs to Phase III
PARTNERSHIPS: Secured new manufacturing agreements
REGULATORY: Received FDA breakthrough therapy designations
OPERATIONS: Improved manufacturing efficiency metrics

Not So Well

PROFITABILITY: Failed to achieve break-even targets
COMPETITION: Lost market share to generic alternatives
FUNDING: Struggled with capital raising initiatives
COMMERCIALIZATION: Delayed product launches impacted revenue
COSTS: Higher than expected R&D expenses

Learnings

DIVERSIFICATION: Single product dependence creates vulnerability
EFFICIENCY: Operational improvements essential for profitability
MARKET: Generic competition requires strategic response
CAPITAL: Alternative funding sources needed for growth
EXECUTION: Better project management improves outcomes

Action Items

PIPELINE: Accelerate Phase III trials for revenue diversification
COSTS: Implement comprehensive cost reduction initiatives
PARTNERSHIPS: Pursue strategic alliances for market expansion
EFFICIENCY: Optimize manufacturing processes for margin improvement
FUNDING: Explore alternative financing options for growth

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Aquestive Therapeutics Market

AI-Powered Insights

Claude

Gemini

GPT

SEC 10-K and 10-Q filings for financial performance data
Company earnings calls and investor presentations
FDA drug approval databases and clinical trial records
Industry reports from pharmaceutical market research firms
Patent databases for intellectual property analysis
Competitive intelligence from pharmaceutical trade publications

Founded: 2004 as MonoSol Rx
Market Share: 8% of buprenorphine market
Customer Base: Healthcare providers and patients
Category:
Specialty Pharmaceuticals
Location: Warren, New Jersey
Zip Code: 07059
Employees: Approximately 140 employees

Competitors

Indivior

Titan Pharmaceuticals

BioDelivery Sciences

Catalent

Patheon

Products & Services

No products or services data available

Distribution Channels

Aquestive Therapeutics Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

SEC 10-K and 10-Q filings for financial performance data
Company earnings calls and investor presentations
FDA drug approval databases and clinical trial records
Industry reports from pharmaceutical market research firms
Patent databases for intellectual property analysis
Competitive intelligence from pharmaceutical trade publications

Problem

Medication adherence issues in CNS disorders
Limited drug delivery options for patients
Complex dosing schedules reduce compliance

Solution

PharmFilm rapid-dissolving technology platform
Simplified dosing regimens improve adherence
Enhanced bioavailability for better outcomes

Key Metrics

Patient adherence rates above 85% target
Revenue growth from diversified portfolio
Manufacturing efficiency and cost reduction

Unique

Proprietary PharmFilm delivery technology
FDA-approved manufacturing capabilities
Strong CNS therapeutic expertise

Advantage

100+ patent portfolio protects technology
Established regulatory approval pathways
Integrated manufacturing facility ownership

Channels

Specialty pharmacy distribution networks
Hospital and healthcare system partnerships
Direct physician and provider outreach

Customer Segments

CNS disorder patients needing adherence
Healthcare providers treating complex cases
Pharmaceutical partners seeking technology

Costs

R&D for pipeline development programs
Manufacturing and operational expenses
Sales and marketing for commercialization

Aquestive Therapeutics Product Market Fit Analysis

Updated: September 18, 2025

Aquestive transforms complex pharmaceutical challenges through proprietary PharmFilm technology, delivering better patient outcomes with improved medication adherence. Their innovative delivery platform addresses critical unmet medical needs in CNS disorders, creating value for patients, providers, and healthcare systems through enhanced therapeutic effectiveness and reduced treatment complexity.

Improved patient adherence outcomes

Reduced healthcare system costs

Enhanced therapeutic effectiveness

Before State

Complex dosing schedules frustrate patients
Poor medication adherence rates
Limited therapeutic options available

After State

Simple, effective dosing improves outcomes
Enhanced patient compliance and satisfaction
Better therapeutic control achieved

Negative Impacts

Treatment failures increase healthcare costs
Patient quality of life deteriorates
Provider frustration with limited options

Positive Outcomes

Reduced healthcare system costs overall
Improved patient quality of life measures
Enhanced provider treatment confidence

Key Metrics

85% patient satisfaction scores

92% treatment adherence rates

Requirements

Advanced PharmFilm technology platform
FDA regulatory approval processes
Strong clinical trial data support

Why Aquestive Therapeutics

Leverage proprietary delivery technology
Focus on underserved patient populations
Partner with key healthcare stakeholders

Aquestive Therapeutics Competitive Advantage

Unique PharmFilm rapid dissolution tech
Established FDA manufacturing approval
Strong clinical efficacy data

Proof Points

85% patient satisfaction in trials
FDA approval for multiple indications

Aquestive Therapeutics Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

SEC 10-K and 10-Q filings for financial performance data
Company earnings calls and investor presentations
FDA drug approval databases and clinical trial records
Industry reports from pharmaceutical market research firms
Patent databases for intellectual property analysis
Competitive intelligence from pharmaceutical trade publications

What You Do

Develop innovative pharmaceutical products

Target Market

Patients with complex therapeutic needs

Differentiation

PharmFilm proprietary technology
CNS therapeutic expertise
Rapid dissolution delivery

Revenue Streams

Product Sales
Contract Manufacturing
Licensing Agreements
Royalties

Aquestive Therapeutics Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

SEC 10-K and 10-Q filings for financial performance data
Company earnings calls and investor presentations
FDA drug approval databases and clinical trial records
Industry reports from pharmaceutical market research firms
Patent databases for intellectual property analysis
Competitive intelligence from pharmaceutical trade publications

Company Operations

Organizational Structure: Public company with functional divisions
Supply Chain: Integrated manufacturing in Warren, NJ
Tech Patents: 100+ patents in drug delivery technology
Website: https://www.aquestive.com

Top Clients

Board Members

Aquestive Therapeutics Competitive Forces

Threat of New Entry

MEDIUM: High regulatory barriers and patent protection limit entry but well-funded biotechs can enter market

Supplier Power

MEDIUM: Specialized raw materials for PharmFilm technology limit supplier options but long-term contracts provide stability

Buyer Power

HIGH: Large pharmacy chains, insurance companies, and hospital systems have significant pricing power and formulary control

Threat of Substitution

HIGH: Alternative delivery methods, generic alternatives, and competing CNS therapies provide multiple substitution options

Competitive Rivalry

HIGH: Intense competition from established players like Indivior, generic manufacturers, and emerging biotechs with 15+ direct competitors

Analysis of AI Strategy

Updated: September 18, 2025 • 2025-Q3 Analysis

Aquestive's AI strategy presents both tremendous opportunity and existential risk. Their PharmFilm platform generates unique datasets perfect for AI optimization, yet current AI capabilities lag competitors significantly. The convergence of AI and pharmaceutical development creates unprecedented opportunities for formulation enhancement and clinical trial efficiency. However, resource constraints demand strategic AI partnerships rather than internal development. Success requires focused AI integration in core competencies while collaborating with AI specialists. The window for AI adoption is narrowing rapidly as competitors advance. Strategic AI implementation could transform their development timeline and competitive position fundamentally.

Indivior Titan Pharmaceuticals BioDelivery Sciences Catalent Patheon

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

Transform lives through pharmaceutical innovation by becoming the global leader in complex therapeutics